{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Absenteeism Week 12","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.362","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Absenteeism Week 12","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.170","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Absenteeism Week 24","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.753","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Absenteeism Week 24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.715","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Presenteeism Week 12","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.077","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Presenteeism Week 12","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.058","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Presenteeism Week 24","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.232","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Presenteeism Week 24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.534","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Work Productivity Loss Week 12","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.079","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Work Productivity Loss Week 12","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.070","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Work Productivity Loss Week 24","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.327","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Work Productivity Loss Week 24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.479","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Activity Impairment Week 12","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.001","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Activity Impairment Week 12","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.005","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Activity Impairment Week 24","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.001","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Activity Impairment Week 24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.030","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.8","value":"3.2"},{"groupId":"OG001","spread":"26.6","value":"-6.7"},{"groupId":"OG002","spread":"22.1","value":"-6.5"}]}],"title":"Absenteeism Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.4","value":"0.9"},{"groupId":"OG001","spread":"31.4","value":"-1.9"},{"groupId":"OG002","spread":"29.5","value":"-2.3"}]}],"title":"Absenteeism Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.4","value":"-4.1"},{"groupId":"OG001","spread":"24.0","value":"-12.0"},{"groupId":"OG002","spread":"24.0","value":"-10.5"}]}],"title":"Presenteeism Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.5","value":"-7.1"},{"groupId":"OG001","spread":"24.9","value":"-11.4"},{"groupId":"OG002","spread":"25.4","value":"-15.6"}]}],"title":"Presenteeism Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.8","value":"-4.2"},{"groupId":"OG001","spread":"26.7","value":"-13.7"},{"groupId":"OG002","spread":"24.8","value":"-12.3"}]}],"title":"Work Productivity Loss Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.4","value":"-6.0"},{"groupId":"OG001","spread":"27.6","value":"-13.2"},{"groupId":"OG002","spread":"32.4","value":"-14.8"}]}],"title":"Work Productivity Loss Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.8","value":"-10.4"},{"groupId":"OG001","spread":"25.5","value":"-16.0"},{"groupId":"OG002","spread":"24.8","value":"-18.1"}]}],"title":"Activity Impairment Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.5","value":"-15.7"},{"groupId":"OG001","spread":"23.7","value":"-20.8"},{"groupId":"OG002","spread":"25.2","value":"-25.8"}]}],"title":"Activity Impairment Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"177"}],"units":"Participants"}],"description":"The WPAI-RA participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. Using 6 questions, it yields four types of scores: absenteeism (work time missed), presenteeism (impairment at work), work productivity loss (overall work impairment), and activity impairment, with outcomes expressed as impairment percentages. Percentage work time missed absenteeism: Q2/(Q2+Q4)\\*100, Percentage impairment while working presenteeism: Q5/10\\*100; Percentage overall work impairment work productivity loss: Q2/(Q2+Q4)+\\[(1-Q2/(Q2+Q4))x(Q5/10)\\]\\*100; Percentage activity impairment activity impairment: Q6/10\\*100. Higher numbers indicate greater impairment and less productivity, that is, worse outcomes.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"MEAN","populationDescription":"mITT population includes all randomized participants who received at least 1 dose of the study drug. Participants were analyzed according to the study drug to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12, Week 24","title":"Percentage Change From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Scores","type":"SECONDARY","unitOfMeasure":"Percentage of Impairment"}